Why do some people with ET, PV & Primary MF respond dramatically to interferon while others have no benefit, or become resistant over time? A new report on our 3-year Interferon Initiative provides insights. Learn more at mpnresearchfoundation.org/mpn-interferon… #MPNsm #MPN

We are excited to announce our 2021 MPN Challenge awards! Each of the 5 research projects will be funded up to $200K over 2 years. 🔬 Learn about the researchers & the focus of their research at mpnresearchfoundation.org/mpn-challenge/. We are grateful to The Leukemia & Lymphoma Society for co-funding a grant. #MPNSM

Today we approved a new treatment for polycythemia vera, a rare blood disease that causes the overproduction of red blood cells. This is the first FDA-approved option that patients with this disease can take regardless of their previous treatment history. fda.gov/news-events/pr…

Breaking MPN news for Polycythemia Vera! Ropeg INFa2b (Besremi) approved for therapy of PV! Great news for #MPNSM community! #Pharmessentia ⁦MPN Research Foundation⁩ ⁦MPN Voice⁩ ⁦MPN_Hub⁩ ⁦MPN Ad&Ed Int'l⁩ ⁦Naveen Pemmaraju, MD⁩ ⁦@UTHealthSAMDA⁩ onclive.com/view/fda-appro…

PV patients. Check out these 10 Quick Facts regarding RoPEG INF (Besremi) for PV. 10 facts MPN patients need to know about FDA approval of Ropegylated int... youtu.be/KhKwDj5xZdg via YouTube Naveen Pemmaraju, MD J.J. Kiladjian Claire Harrison @UTHealthSAMDA #mpnsm

Several MPNRF Board Members have committed to personally contribute $80,000 if 100 people donate TODAY. Be 1 of 100 by making a donation at mpnresearchfoundation.org/donate. Together, we advance MPN research! #MPNsm #GivingTuesday

Heads up!! TODAY is #GivingTuesday Please support research towards better treatments for #MPN patients by supporting MPN Research Foundation Be one of the 100 to help us unlock $80,000! mpnresearchfoundation.org/donate

Congrats to PedsHemeDoc and all MPN Heroes! Thank you for your clinical and research leadership and the compassion you show to #MPN patients and their families!!

#ASH21 #MPN #CD123 in #myelofibrosis, Great talk and another option for refractory patients, notice median #survival 26.6 months Naveen Pemmaraju, MD Abdulraheem Yacoub. Congrats!

Thanks to ASH and mentorship from Gaby Hobbs for the opportunity to present our work on #mpnsm and responses to covid vaccination at #ASH21 !

Heads up! All #mpn researchers - don't miss this opportunity for funding through FDA's grant program. #mpnsm Please RT and share with colleagues.

Exciting trial update at #ASH21 including this overview of the iron metabolism and erythropoiesis from MPN Research Foundation's previously funded researcher Yelena Ginzburg. Very interested to see further results in this trial of rusfertide in PV patients with high phlebotomy need.

So great to see these results presented at #ASH21!! Thank you to all researchers, clinicians and patients for doing your part to move research forward toward better options for patients!

Dr. Richard T. Silver discusses using interferon in the treatment of myeloproliferative neoplasms (MPNs) and a related 3-year global initiative led by the MPN Research Foundation where he serves as an advisor. Full interview: bit.ly/3EugZ5H (cc: Targeted Oncology) #MPNsm

This important report was made possible by #patients Thank you for sharing your voices. #mpnsm

👉👉👉Our new paper just out in PubMed: Ruxolitinib re-treatment in patients w/Myelofibrosis 🙌 Acta Haematologica Karger Publishers | karger.com/Article/Abstra… | Aaron Gerds MD, MS Naveen Pemmaraju, MD | #MPNSM

ICYMI vital patient insight into living with an #MPN

Hot off the press!! So excited to follow this research and see the impact it will have on #mpn research and treatments!

Our work on structural racism & AML outcomes is out in @BloodJournal! This was a Chicago-wide collab led by Dr. Abraham & Irum Khan. The big takeaway - structural racism accounts for almost all of the survival disparity in Black & Hispanic pts #leusm ashpublications.org/blood/article/…